“FLOW Trial: Semaglutide and 24% Fewer Kidney Events The First Dedicated GLP-1 Kidney-Outcomes Trial in Type 2 Diabetes and CKD”. Diabzen, vol. 4, no. 20, July 2026, pp. 40-41, https://thediabzen.com/index.php/d/article/view/63.